<DOC>
	<DOCNO>NCT01115491</DOCNO>
	<brief_summary>This Phase II , national , multicenter , open-label , non-comparative study investigate efficacy safety bevacizumab temozolomide patient recurrent glioblastoma multiforme ( GBM ) first treatment failure . Patients receive bevacizumab 10 mg/kg intravenously every two week disease progression , consent withdrawal , unacceptable toxicity . Anticipated time study treatment 12-24 month .</brief_summary>
	<brief_title>A Study Bevacizumab Extended Treatment Temozolomide Patients With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Age &gt; = 18 year Histological diagnosis glioblastoma multiforme ( GBM ) document surgical resection biopsy . They patient first relapse treat radiotherapy chemotherapy chemotherapy base temozolomide 150200 mg/m2 day 1 5 every 28 day ( Stupp regimen ) least three cycle . At least 4 week must lapse since previous chemotherapy 3 month since last dose radiotherapy . Use effective contraceptive method patient partner . Stable decrease corticosteroid dose five day prior study entry Adequate hematological function Adequate liver function Adequate kidney function Signs recent bleed MRI brain . However , patient clinically asymptomatic presence hemosiderin , resolve bleeding change relate surgery , presence punctate hemorrhage tumor allow participate study . Prior treatment bevacizumab Poorly control arterial hypertension History hypertensive crisis hypertensive encephalopathy New York Health Association ( NYHA ) Class II higher congestive heart failure History myocardial infarction unstable angina pectoris within six month study entry History stroke TIA within six month study entry Significant vascular disease within six month study entry History hemoptysis &gt; grade 2 accord NCI CTC criterion within one month study entry Evidence bleed diathesis coagulopathy ( absence therapeutic anticoagulation ) Major surgery , open biopsy , intracranial biopsy , ventriculoperitoneal shunt , major traumatic lesion within 28 day study entry . Core needle biopsy ( exclude intracranial biopsy ) minor surgery within seven day randomization . Placement central vascular access device ( CVAD ) perform two day prior bevacizumab administration History abdominal fistula gastrointestinal perforation within six month study entry History intracranial abscess within six month randomization Any prior malignant neoplasm treat curative intent five year prior study entry , except adequately control limited basal cell carcinoma skin , squamous cell carcinoma skin , carcinoma situ cervix Patients metabolic psychological disease Hypersensitivity product derive Chinese hamster ovary cell humanize recombinant human antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>